EUVIMEDEUVIMED entdecken
Crossref

Progression free survival by the treatment with Cabozatinib in a case of BRAF mutated Radioiodine refractory recurrent metastatic Papillary Carcinoma Thyroid

Sylvia Akter, Md Abu Hanif, Muhammad Ali Azad, Monsur Alam, Salahuddin Ahmed Sohan

Bangladesh Journal of Otorhinolaryngology · 21.04.2026 · 31 (2) · 86-94

DOI: 10.3329/bjo.v31i2.89000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bangladesh Journal of Otorhinolaryngology, online erschienen am 21.04.2026. Verfasst von Sylvia Akter und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic differentiated thyroid carcinoma that fails to respond to radioactive iodine (RAI) therapy carries a poor prognosis with frequent recurrence. Multikinase inhibitors may help slow disease progression, particularly in cases with BRAF mutations, whereRAI refractoriness is common. Agents such as dabrafenib, trametinib, lenvatinib, and cabozantinib have shown therapeutic benefit. This report focuses on the clinical course of a 65 year old male with BRAF (V600E)–mutated, RAI refractory, recurrent metastatic papillary thyroid carcinoma (PTC) and his response to lenvatinib and cabozantinib.The patient initially presented with a painless anterior neck swelling, diagnosed as PTC by FNAC. CT imaging revealed subcentimetric nodal involvement, and heunderwent total thyroidectomy with central compartment clearance and selective neck dissection (stageT3N1Mx). Postoperative RAI ablation (150 mCi) showed no significant uptake, though the patient remained symptom free with normal thyroglobulin and TSH levels. One year later, follow up evaluations detected metastatic cervical lymph nodes. PET CT confirmed metabolically active disease in bilateral cervical nodes and pulmonary nodules. He subsequently underwent repeat neck dissection followed byRAI, but recurrence persisted due to aggressive tumor behavior. Molecular analysis later identified a BRAF (V600E) mutation. Lenvatinib therapy was initiated to slow disease progression; however, despite partial response, the patient experienced hypertension and further nodal recurrence after multiple RAI exposures. Following additional surgery, cabozantinib was introduced, resulting in noticeable regression of metastatic neck nodes despite some adverse effects.This case highlights the aggressive nature of BRAF positive, RAI refractory PTC and underscores the therapeutic value of targeted multikinase inhibitors. Cabozantinib offered disease control in an otherwise rapidly progressive clinical scenario. This case emphasizes the importance of early molecular profiling and the role of alternative systemic therapies in managing advanced refractory thyroid carcinoma. Bangladesh J Otorhinolaryngol 2025; 31(2): 86-94

Zitieren

APA

Akter, S., Hanif, M. A., Azad, M. A., Alam, M., & Sohan, S. A. (2026). Progression free survival by the treatment with Cabozatinib in a case of BRAF mutated Radioiodine refractory recurrent metastatic Papillary Carcinoma Thyroid. Bangladesh Journal of Otorhinolaryngology, 31(2), 86-94. https://doi.org/10.3329/bjo.v31i2.89000

Vancouver

Akter S, Hanif MA, Azad MA, Alam M, Sohan SA. Progression free survival by the treatment with Cabozatinib in a case of BRAF mutated Radioiodine refractory recurrent metastatic Papillary Carcinoma Thyroid. Bangladesh Journal of Otorhinolaryngology. 2026;31(2):86-94. doi:10.3329/bjo.v31i2.89000

BibTeX
@article{Akter2026,
  author = {Akter, Sylvia and Hanif, Md Abu and Azad, Muhammad Ali and Alam, Monsur and Sohan, Salahuddin Ahmed},
  title = {Progression free survival by the treatment with Cabozatinib in a case of BRAF mutated Radioiodine refractory recurrent metastatic Papillary Carcinoma Thyroid},
  journal = {Bangladesh Journal of Otorhinolaryngology},
  year = {2026},
  volume = {31},
  number = {2},
  pages = {86--94},
  doi = {10.3329/bjo.v31i2.89000}
}
Kostenlos starten →